Kyushu University Academic Staff Educational and Research Activities Database
List of Reports
Tatsuro Tajiri Last modified date:2023.12.06

Professor / Pediatric Surgery / Department of Clinical Medicine / Faculty of Medical Sciences


Reports
1. T TAJIRI, H MAKI, K SAKUMI, M SEKIGUCHI, FUNCTIONAL COOPERATION OF MUTT, MUTM AND MUTY PROTEINS IN PREVENTING MUTATIONS CAUSED BY SPONTANEOUS OXIDATION OF GUANINE-NUCLEOTIDE IN ESCHERICHIA-COLI, JOURNAL OF CELLULAR BIOCHEMISTRY, Vol.366,257-267, p.276, 1995.03.
2. T Tajiri, S Suita, K Shono, M Kubota, T Taguchi, K Yamanouchi, S Noguchi, M Tsuneyoshi, Lung cancer in a child with a substantial family history of cancer, EUROPEAN JOURNAL OF PEDIATRIC SURGERY, Vol.9, No.6, pp.409-412, 1999.12, The occurrence of primary lung cancer is rare in childhood. The case of an Ii-year-old boy with primary lung cancer is presented in this report. He had a substantial family history of cancer. His chief complaint was coughing with right chest pain. A chest radiograph showed a coin lesion in the right lower lung. A right lower lobectomy revealed a squamous cell carcinoma (stage IIIA at Japanese TNM classification). Systemic chemotherapy using cisplatin, vindesine, THP-adriamycin and cyclophosphamide was performed. Six months after surgery, a recurrent tumor occurred. An analysis of the familial cancer related genes (p53 gene and mismatch repair gene) showed no abnormality..
3. T Tajiri, S Tanaka, K Shono, Y Kinoshita, Y Fujii, S Suita, K Ihara, T Hara, Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma, CANCER LETTERS, 10.1016/S0304-3835(01)00434-7, Vol.166, No.1, pp.89-94, 2001.05, The amplification of the N-myc gene and a gain of the chromosome 17q arm correlate with an unfavorable outcome in patients with neuroblastoma. In this study, we determined the gene dosage of the N-myc gene (located at 2p24) and Survivin gene (located at 17q25) using the p53 gene (located at 17p13) as the internal control gene by the TaqMan polymerase chain reaction (PCR)-based gene dosage analysis in 25 neuroblastoma samples. Based on the assumption that the gene dosages of each gene of a normal individual lymphocytes are 1.0, 11 of the 25 cases with a corrected gene dosage of N-myc (N-myc/p53) of more than 2.0 had a more unfavorable prognosis than the 14 cases with a N-myc gene dosage of less than 2.0 (5-year survival rate: 18 vs. 71%, P < 0.01). Ten of 25 cases with a corrected Survivin gene dosage (Survivin/p53) of more than 2.0 had a more unfavorable prognosis than the 15 cases with a Survivin gene dosage of less than 2.0 (5-year survival rate: 10 vs. 67%, P < 0.01). This quantitative PCR system is considered to be useful for quickly and accurately evaluating the degree of malignancy of neuroblastoma in order to select the optimal treatment. (C) 2001 Elsevier Science Inland Ltd. All rights reserved..
4. T Tajiri, S Suita, Y Sera, H Takamatsu, H Mizote, A Nagasaki, N Kurosaki, N Handa, T Hara, J Okamura, S Miyazaki, T Sugimoto, K Kawakami, H Eguchi, M Tsuneyoshi, Clinical and biologic characteristics for recurring neuroblastoma at mass screening cases in Japan, CANCER, 10.1002/1097-0142(20010715)92:23.0.CO;2-C, Vol.92, No.2, pp.349-353, 2001.07, BACKGROUND. It is said that most cases detected by neuroblastoma mass screening at 6 months of age tend to have a favorable clinical course after a surgical resection either with or without mild chemotherapy. However, a feu cases have an unfavorable outcome. In the current study, the authors analyzed the clinical and biologic characteristics for recurring neuroblastoma in mass screening cases.
METHODS. In 245 cases detected through mass screening in the Kushu area in Japan, the clinical data and biologic features (N-myc status, DNA ploidy, Shimada histology, neuron-specific enolase INSE), ferritin) were investigated, whereas, in particular, the data for recurring cases also were analyzed.
RESULTS. Of 245 cases, 28 tumors had one or more biologically unfavorable prognostic factors, and 6 patients experienced recurrence. Three of the six patients with recurring disease underwent a complete resection of the primary tumor, whereas three cases had undergone an incomplete resection of the tumor. Regarding the initial chemotherapy, three cases received mild chemotherapy, two cases received no chemotherapy, and one case had high-dose multidrug chemotherapy. Regarding biologic prognostic factors, four of six cases with recurring disease had one or more unfavorable factors, whereas two cases had no unfavorable factors. Regarding the outcome after recurrence, four cases are CR, one case has a stable residual tumor, and one case died of disease with N-myc amplification.
CONCLUSIONS. Most neuroblastomas detected by mass screening at 6 months of age have biologically favorable factors. However, approximately 10% of the cases had one or more unfavorable factors and thus might have a higher risk of recurrence than the patients with no unfavorable factors. Conversely, some cases with recurring disease had no unfavorable factors; however, the reason for this is still unclear. A long-term follow-up for mass screening cases is important, and it also might be necessary to research the established biologic factors and identify other new prognostic factors. (C) 2001 American Cancer Society..
5. Treatment for refractory pediatric malignant germ cell tumors.
6. Clinical efficacy of irinotecan to refractory neuroblastoma.
7. The role of surgical intervention in the treatment for neuroblastoma.
8. Establishment of highly sensitive analysis of prognostic factors in neuroblastoma.
9. Koichiro Abe, Masayuki Sasaki, Yasuo Kuwabara, Hirofumi Koga, Shingo Baba, Koichiro Kaneko, Kazutaka Hayashi, Yoshiyuki Shioyama, Tatsuro Tajiri, Sachiyo Suita, Hiroshi Honda, Extraosseous accumulation of 99mTc-HMDP to radiation nephropathy, mimicking recurrent neuroblastoma, Annals of Nuclear Medicine, 10.1007/BF02986333, Vol.19, No.1, pp.35-40, 2005.02, Objective: The aim of this study is to clarify the period of extraosseous accumulation of 99mTc-hydroxymethylenediphosphonate (HMDP) to radiation nephropathy mimicking recurrent or remnant neuroblastoma in the pararenal region. Methods: We reviewed five neuroblastoma and one ganglioneuroblastoma patients (2 boys and 4 girls aged 1-9 years) who underwent 99mTc-HMDP bone scintigraphies periodically before and after radiation therapy. Results: Increased renal uptake coincident with the radiation port appeared in 5 of 6 patients from O to 3 months (mean 1.7 months), and persisted up to 7 months after the completion of radiotherapy. Renal uptake of 99mTc-HMDP was gradually decreased, and eventually became accumulation defects in 5 of 6 patients from 6 to 17 months (mean 8.9 months) after radiotherapy. Conclusion: When extraosseous accumulation is found after radiation therapy in neuroblastoma patients, radiation nephropathy would be a candidate in the differential diagnosis besides recurrent or remnant tumor..
10. P-236A The usefulness of laparoscopy for diagnosia and treatment of non palpable testis(Urology 2, the 44th Annual Meeting of Japanese Society of Pediatric Surgeons).
11. A case of a neonatal hepatoblastoma treated by primary radical operation
We treated a 17-days-old girl with hepatic mass of 9cm in size protruded from right hepatic lobe, which was preoperatively diagnosed a hepatoblastoma categorized as PRETEXT II. She underwent right lobe hepatectomy at 27-days-old. Postoperative chemotherapy with a modified regimen, low CITA, in which dosage was reduced following the JPLT-2 protocol, was prescribed without any obvious side effects. Primary resection under appropriate condition is an alternative treatment, which is safe and effective..
12. P-199 De novo yolk sac tumor associated with the Peutz-Jeghers syndrome in childhood(Poster Session Oncology 3,Better Life for Sick Children, Better Future for Pediatric Surgery,the 45th Annual Meeting of Japanese Society of Pediatric Surgeons).
13. B-081 Implication of transumbilical approach using a half circumumbilical incision for neonatal surgical diseases(Oral Presentation Endoscopic surgery, operative techniques,Better Life for Sick Children, Better Future for Pediatric Surgery,the 45th Annual.
14. A case of postoperative intussusceptions after the surgical resection of neuroblastoma
We experienced a case of post-operative intussusception that occurred after surgical resection of a neuroblastoma. The post-operative intussusceptions of children are rare with only 89 cases being documented in Japan. The post-operative intussusceptions of children demonstrate such clinical features as: occurrence within one week after an operation, high incidence of ileo-ileo type, low incidence of bloody excrement, and few cases requiring enterectomy. As for the cause of post-operative intussusceptions, many cases occurred after the surgical resection of retroperitoneal tumors, especially neuroblastoma. It is suggested that the surgery on the retroperitoneal tumor affected the retroperitoneal nerve and ganglion. In addition it caused a disorder in the movement of intestine that occurred during the post-operative intussusceptions..
15. Experience of pediatric renal cell carcinoma utilizing of dendritic cell immunotherapy
Dendirtic cell (DC) is the most effective antigen-presenting cell, inducing a T cell response. After the establishment of abundant DC culture method, clinical trials utilizing DC have been performed against many cancers. We observed a pediatric advanced renal cell carcinoma (RCC) in an 11 year old boy, treated with DC immunotherapy, which was separated from monocytes collected by apheresis, and exposed by the patient's tumor lysate. After DC immunotherapy, the disease became progressive, however, hilar lymph nodes showed partial regression. Immunotherapy utilizing DC was well tolerated, but its clinical effect was not sufficient. Now, we are developing a new strategy for DC-based immuno-gene therapy..
16. A pediatric case of multiple hepatic focal nodular hyperplasia-like lesions presenting as atypical imaging and histopathological findings
We encountered the case of a 10-year-old girl presenting with multiple hepatic focal nodular hyperplasia (FNH)-like lesions, which were difficult to differentiate from hepatocellular carcinoma (HCC) because of their atypical presentation. She was referred to our institution for an incidentally detected multiple liver mass during the follow-up for thigh pain. Enhanced MRI with gadolinium ethoxybenzyl diethy­lenetriamine-pentaacetic acid (Gd-EOB-DTPA) showed compatible observation in most nodules. However, a mass in S3 showed hypointensity in the hepatocellular phase, which is characteristic of HCC. We performed laparoscopic tumorectomy to rule out malignancy. A histopathological study showed benign hyperplastic lesions, but further classification was difficult. Thus, our final diagnosis was FNH-like lesions.<br/>FNH-like lesions are hyperplastic lesions caused by a vascular abnormality similar to a typical FNH, although their features are not compatible with those of FNH. This disease may be difficult to distinguish from FNH or HCC because the imaging findings as well as the histopathological findings are atypical. We have to consider this disease when we see an imaging study indicating HCC, despite a benign clinical picture..
17. T TAJIRI, H MAKI, K SAKUMI, M SEKIGUCHI, FUNCTIONAL COOPERATION OF MUTT, MUTM AND MUTY PROTEINS IN PREVENTING MUTATIONS CAUSED BY SPONTANEOUS OXIDATION OF GUANINE-NUCLEOTIDE IN ESCHERICHIA-COLI, JOURNAL OF CELLULAR BIOCHEMISTRY, Vol.366,257-267, p.276, 1995.03.
18. T Tajiri, S Suita, K Shono, M Kubota, T Taguchi, K Yamanouchi, S Noguchi, M Tsuneyoshi, Lung cancer in a child with a substantial family history of cancer, EUROPEAN JOURNAL OF PEDIATRIC SURGERY, Vol.9, No.6, pp.409-412, 1999.12, The occurrence of primary lung cancer is rare in childhood. The case of an Ii-year-old boy with primary lung cancer is presented in this report. He had a substantial family history of cancer. His chief complaint was coughing with right chest pain. A chest radiograph showed a coin lesion in the right lower lung. A right lower lobectomy revealed a squamous cell carcinoma (stage IIIA at Japanese TNM classification). Systemic chemotherapy using cisplatin, vindesine, THP-adriamycin and cyclophosphamide was performed. Six months after surgery, a recurrent tumor occurred. An analysis of the familial cancer related genes (p53 gene and mismatch repair gene) showed no abnormality..
19. T Tajiri, S Tanaka, K Shono, Y Kinoshita, Y Fujii, S Suita, K Ihara, T Hara, Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma, CANCER LETTERS, 10.1016/S0304-3835(01)00434-7, Vol.166, No.1, pp.89-94, 2001.05, The amplification of the N-myc gene and a gain of the chromosome 17q arm correlate with an unfavorable outcome in patients with neuroblastoma. In this study, we determined the gene dosage of the N-myc gene (located at 2p24) and Survivin gene (located at 17q25) using the p53 gene (located at 17p13) as the internal control gene by the TaqMan polymerase chain reaction (PCR)-based gene dosage analysis in 25 neuroblastoma samples. Based on the assumption that the gene dosages of each gene of a normal individual lymphocytes are 1.0, 11 of the 25 cases with a corrected gene dosage of N-myc (N-myc/p53) of more than 2.0 had a more unfavorable prognosis than the 14 cases with a N-myc gene dosage of less than 2.0 (5-year survival rate: 18 vs. 71%, P < 0.01). Ten of 25 cases with a corrected Survivin gene dosage (Survivin/p53) of more than 2.0 had a more unfavorable prognosis than the 15 cases with a Survivin gene dosage of less than 2.0 (5-year survival rate: 10 vs. 67%, P < 0.01). This quantitative PCR system is considered to be useful for quickly and accurately evaluating the degree of malignancy of neuroblastoma in order to select the optimal treatment. (C) 2001 Elsevier Science Inland Ltd. All rights reserved..
20. T Tajiri, S Suita, Y Sera, H Takamatsu, H Mizote, A Nagasaki, N Kurosaki, N Handa, T Hara, J Okamura, S Miyazaki, T Sugimoto, K Kawakami, H Eguchi, M Tsuneyoshi, Clinical and biologic characteristics for recurring neuroblastoma at mass screening cases in Japan, CANCER, 10.1002/1097-0142(20010715)92:23.0.CO;2-C, Vol.92, No.2, pp.349-353, 2001.07, BACKGROUND. It is said that most cases detected by neuroblastoma mass screening at 6 months of age tend to have a favorable clinical course after a surgical resection either with or without mild chemotherapy. However, a feu cases have an unfavorable outcome. In the current study, the authors analyzed the clinical and biologic characteristics for recurring neuroblastoma in mass screening cases.
METHODS. In 245 cases detected through mass screening in the Kushu area in Japan, the clinical data and biologic features (N-myc status, DNA ploidy, Shimada histology, neuron-specific enolase INSE), ferritin) were investigated, whereas, in particular, the data for recurring cases also were analyzed.
RESULTS. Of 245 cases, 28 tumors had one or more biologically unfavorable prognostic factors, and 6 patients experienced recurrence. Three of the six patients with recurring disease underwent a complete resection of the primary tumor, whereas three cases had undergone an incomplete resection of the tumor. Regarding the initial chemotherapy, three cases received mild chemotherapy, two cases received no chemotherapy, and one case had high-dose multidrug chemotherapy. Regarding biologic prognostic factors, four of six cases with recurring disease had one or more unfavorable factors, whereas two cases had no unfavorable factors. Regarding the outcome after recurrence, four cases are CR, one case has a stable residual tumor, and one case died of disease with N-myc amplification.
CONCLUSIONS. Most neuroblastomas detected by mass screening at 6 months of age have biologically favorable factors. However, approximately 10% of the cases had one or more unfavorable factors and thus might have a higher risk of recurrence than the patients with no unfavorable factors. Conversely, some cases with recurring disease had no unfavorable factors; however, the reason for this is still unclear. A long-term follow-up for mass screening cases is important, and it also might be necessary to research the established biologic factors and identify other new prognostic factors. (C) 2001 American Cancer Society..
21. Treatment for refractory pediatric malignant germ cell tumors.
22. Clinical efficacy of irinotecan to refractory neuroblastoma.
23. The role of surgical intervention in the treatment for neuroblastoma.
24. Establishment of highly sensitive analysis of prognostic factors in neuroblastoma.
25. Koichiro Abe, Masayuki Sasaki, Yasuo Kuwabara, Hirofumi Koga, Shingo Baba, Koichiro Kaneko, Kazutaka Hayashi, Yoshiyuki Shioyama, Tatsuro Tajiri, Sachiyo Suita, Hiroshi Honda, Extraosseous accumulation of 99mTc-HMDP to radiation nephropathy, mimicking recurrent neuroblastoma, Annals of Nuclear Medicine, 10.1007/BF02986333, Vol.19, No.1, pp.35-40, 2005.02, Objective: The aim of this study is to clarify the period of extraosseous accumulation of 99mTc-hydroxymethylenediphosphonate (HMDP) to radiation nephropathy mimicking recurrent or remnant neuroblastoma in the pararenal region. Methods: We reviewed five neuroblastoma and one ganglioneuroblastoma patients (2 boys and 4 girls aged 1-9 years) who underwent 99mTc-HMDP bone scintigraphies periodically before and after radiation therapy. Results: Increased renal uptake coincident with the radiation port appeared in 5 of 6 patients from O to 3 months (mean 1.7 months), and persisted up to 7 months after the completion of radiotherapy. Renal uptake of 99mTc-HMDP was gradually decreased, and eventually became accumulation defects in 5 of 6 patients from 6 to 17 months (mean 8.9 months) after radiotherapy. Conclusion: When extraosseous accumulation is found after radiation therapy in neuroblastoma patients, radiation nephropathy would be a candidate in the differential diagnosis besides recurrent or remnant tumor..
26. P-236A The usefulness of laparoscopy for diagnosia and treatment of non palpable testis(Urology 2, the 44th Annual Meeting of Japanese Society of Pediatric Surgeons).
27. A case of a neonatal hepatoblastoma treated by primary radical operation
We treated a 17-days-old girl with hepatic mass of 9cm in size protruded from right hepatic lobe, which was preoperatively diagnosed a hepatoblastoma categorized as PRETEXT II. She underwent right lobe hepatectomy at 27-days-old. Postoperative chemotherapy with a modified regimen, low CITA, in which dosage was reduced following the JPLT-2 protocol, was prescribed without any obvious side effects. Primary resection under appropriate condition is an alternative treatment, which is safe and effective..
28. P-199 De novo yolk sac tumor associated with the Peutz-Jeghers syndrome in childhood(Poster Session Oncology 3,Better Life for Sick Children, Better Future for Pediatric Surgery,the 45th Annual Meeting of Japanese Society of Pediatric Surgeons).
29. B-081 Implication of transumbilical approach using a half circumumbilical incision for neonatal surgical diseases(Oral Presentation Endoscopic surgery, operative techniques,Better Life for Sick Children, Better Future for Pediatric Surgery,the 45th Annual.
30. A case of postoperative intussusceptions after the surgical resection of neuroblastoma
We experienced a case of post-operative intussusception that occurred after surgical resection of a neuroblastoma. The post-operative intussusceptions of children are rare with only 89 cases being documented in Japan. The post-operative intussusceptions of children demonstrate such clinical features as: occurrence within one week after an operation, high incidence of ileo-ileo type, low incidence of bloody excrement, and few cases requiring enterectomy. As for the cause of post-operative intussusceptions, many cases occurred after the surgical resection of retroperitoneal tumors, especially neuroblastoma. It is suggested that the surgery on the retroperitoneal tumor affected the retroperitoneal nerve and ganglion. In addition it caused a disorder in the movement of intestine that occurred during the post-operative intussusceptions..
31. Experience of pediatric renal cell carcinoma utilizing of dendritic cell immunotherapy
Dendirtic cell (DC) is the most effective antigen-presenting cell, inducing a T cell response. After the establishment of abundant DC culture method, clinical trials utilizing DC have been performed against many cancers. We observed a pediatric advanced renal cell carcinoma (RCC) in an 11 year old boy, treated with DC immunotherapy, which was separated from monocytes collected by apheresis, and exposed by the patient's tumor lysate. After DC immunotherapy, the disease became progressive, however, hilar lymph nodes showed partial regression. Immunotherapy utilizing DC was well tolerated, but its clinical effect was not sufficient. Now, we are developing a new strategy for DC-based immuno-gene therapy..
32. A pediatric case of multiple hepatic focal nodular hyperplasia-like lesions presenting as atypical imaging and histopathological findings
We encountered the case of a 10-year-old girl presenting with multiple hepatic focal nodular hyperplasia (FNH)-like lesions, which were difficult to differentiate from hepatocellular carcinoma (HCC) because of their atypical presentation. She was referred to our institution for an incidentally detected multiple liver mass during the follow-up for thigh pain. Enhanced MRI with gadolinium ethoxybenzyl diethy­lenetriamine-pentaacetic acid (Gd-EOB-DTPA) showed compatible observation in most nodules. However, a mass in S3 showed hypointensity in the hepatocellular phase, which is characteristic of HCC. We performed laparoscopic tumorectomy to rule out malignancy. A histopathological study showed benign hyperplastic lesions, but further classification was difficult. Thus, our final diagnosis was FNH-like lesions.<br/>FNH-like lesions are hyperplastic lesions caused by a vascular abnormality similar to a typical FNH, although their features are not compatible with those of FNH. This disease may be difficult to distinguish from FNH or HCC because the imaging findings as well as the histopathological findings are atypical. We have to consider this disease when we see an imaging study indicating HCC, despite a benign clinical picture..
33. 両側Wilms腫瘍の2例の臨床経過とWT1遺伝子解析.
34. 肝移植後早期合併症 生体肝移植術後に門脈血流確保が困難であった胆道閉鎖症の1例
11ヵ月男児。40生日時に胆道閉鎖症で肝門部空腸吻合術を施行されたが、減黄不良で肝機能障害が進行し、母親をドナーとする左葉グラフトを用いた生体肝移植を施行した。術中所見で門脈径は細く、ドナーのIMVを用いた門脈形成と、レシピエントの肝周囲に増生したcoronary veinの結紮を施行した。肝静脈はドナーの左肝静脈とレシピエントの中肝静脈を吻合し、肝動脈はドナーの左冠動脈と中肝動脈を一穴に形成してレシピエントの肝動脈と吻合した。再灌流直後の門脈血流は良好であったが、動脈吻合後に血流は消失し、門脈内に血栓を認め、血栓除去後に再吻合した。術後の減黄は良好で、肝障害も改善傾向にあったが、門脈血流の流量は低下傾向を示した。移植後8日目に肝逸脱酵素の急激な上昇を認め、血管造影で門脈血栓症と診断し、左腎静脈-大伏在静脈グラフト-門脈臍部吻合で門脈再建を施行した。その4日後に再度の門脈血栓症を来たし、脾動脈-グラフト吻合、脾臓摘出術を施行し、門脈血流は良好となった。しかし、その後腹腔内出血を繰り返し、多臓器不全に陥って移植後30日目に死亡した。剖検では移植肝の肝梗塞を認めた。.
35. T. Hishiki, T. Kuroda, T. Tajiri, A. Yoneda, K. Tokiwa, T. Muraji, K. Sugito, K. Ise, Y. Kinoshita, S. Uehara, K. Matsumoto, M. Kumagai, T. Soejima, T. Takimoto, H. Takahashi, T. Kamijo, A. Makimoto, J. Hara, H. Ikeda, A. Nakagawara, REVIEW OF SURGICAL TREATMENT IN PATIENTS ENROLLED IN THE PHASE II STUDY NB-HR07 FOR ADVANCED NEUROBLASTOMA- A REPORT FROM JAPAN NEUROBLASTOMA STUDY GROUP (JNBSG), PEDIATRIC BLOOD & CANCER, Vol.60, p.31, 2013.09.
36. 瓜生 久美子, 西村 力, 吉田 健一, 関 正史, 星野 論子, 吉田 美沙, 加藤 元博, 樋渡 光輝, 林 泰秀, 田尻 達郎, 中川原 章, 小川 誠司, 滝田 順子, 日本神経芽腫研究グループ, 神経芽腫大規模検体におけるgenetic landscapeと予後解析(Landscape of genetic lesions in 442 patients with neuroblastoma), 日本癌学会総会記事, Vol.73回, pp.E-2062, 2014.09.
37. 局所神経芽腫におけるImage Defined の Risk Factor (IDRF) に対する新ガイドラインの手術リスク評価の妥当性.
38. 限局性神経芽腫に対する IDRFs に基づいた外科治療ガイドラインの妥当性と有用性:2施設共同研究.
39. 異所性甲状腺腫による小児原発性副甲状腺機能亢進症の一例.
40. 異所性甲状腺腫による小児原発性副甲状腺機能亢進症の一例.
41. 瓜生 久美子, 吉田 健一, 片岡 圭亮, 関 正史, 樋渡 光輝, 林 泰秀, 中澤 温子, 瀧本 哲也, 田尻 達郎, 中川原 章, 宮野 悟, 小川 誠司, 滝田 順子, 神経芽腫500例における遺伝子背景と病理学的検討, 日本癌学会総会記事, Vol.75回, pp.E-1014, 2016.10.
42. ラジオナビゲーションおよび術中血中PTH測定併用による縦隔内異所性副甲状腺に対する胸腔鏡下全摘出術.
43. H. Fuji, T. Soejima, M. Nozaki, H. Masaki, K. Nozawa, O. Miyazaki, M. Kitamura, T. Tajiri, T. Koshinaga, H. Hosoi, E. HIyama, T. Takimoto, M. Fukuzawa, N. Kiyokawa, H. Junichi, Radiotherapy Quality Management System for Conducting Nationwide Clinical Trials: An Instrument Established by the Japan Chidlren's Cancer Group, PEDIATRIC BLOOD & CANCER, Vol.63, p.S91, 2016.11.
44. T Tajiri, S Suita, K Shono, M Kubota, Y Fujii, E Oki, S Oda, Y Maehara, K Sugimachi, A microsatellite instability analysis in neuroblastoma based on a high resolution fluorescent microsatellite analysis, CANCER LETTERS, 10.1016/S0304-3835(97)00448-5, Vol.124, No.1, pp.59-63, 1998.02, It has recently been reported that mismatch repair enzymes, which are one type of DNA repair enzymes, are the causative genes for a major group of hereditary non-polyposis colon cancers (HNPCC). Abnormalities in the mismatch repair system can be monitored by observing instability at the microsatellite loci (MSI) in cancer cells. MSI has been reported not only in tumors associated with hereditary non-polyposis colorectal cancer but also in sporadic forms of various tumors, No correlation between pediatric malignant tumors and the mismatch repair system has yet been reported. In the present study, we examined the frequency of MSI in 21 neuroblastomas, which are the most common solid tumors in childhood, using a high resolution fluorescent microsatellite analysis. MSI on five microsatellite loci was detected in none of the 21 samples. Other mechanisms independent of mismatch repair deficiency may thus play a role in both tumorigenesis and the development of neuroblastoma. (C) 1998 Elsevier Science Ireland Ltd..
45. A Suminoe, A Matsuzaki, N Kinukawa, T Inamitsu, T Tajiri, S Suita, T Hara, Rapid somatic growth after birth in children with neuroblastoma: A survey of 1718 patients with childhood cancer in Kyushu-Okinawa district, JOURNAL OF PEDIATRICS, 10.1016/S0022-3476(99)70412-9, Vol.134, No.2, pp.178-184, 1999.02, Objective: To evaluate the association of somatic growth fr om birth through diagnosis with the development of childhood cancer.
Methods: The weights and heights of 1718 children with cancers were determined and converted into standard deviation (SD) scores, both at birth and at diagnosis, by using the means and SD values of the general population.
Results: Among patients with neuroblastoma and acute lymphoblastic leukemia, the percentages of children with body weight and height over mean +2 SDs were significantly higher at diagnosis than the expected value in the general population. The percentage of children with neuroblastoma and body weight over mean +2 SD increased significantly From birth through diagnosis (P = .04). Although the medians of weight SD scores decreased from birth through diagnosis in patients with representative cancers except for neuroblastoma, the value significantly increased in patients with neuroblastoma diagnosed before 1 year of age (P = .03), especially in those whose cancer was detected by mass screening at 6 months of age (P < .01).
Conclusions: Rapid somatic growth from birth through diagnosis in patients with neuroblastoma diagnosed before 1 year of age suggests a possible involvement of certain growth factors in these patients..
46. T Tajiri, K Shono, Y Fujii, S Noguchi, Y Kinoshita, M Tsuneyoshi, S Suita, Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization, JOURNAL OF PEDIATRIC SURGERY, Vol.34, No.11, pp.1615-1619, 1999.11, Background/Purpose: The N-myc amplification status in neuroblastoma has been evaluated previously for the whole tumor by the Southern blot method. The aim of this study is to evaluate the effectiveness of the fluorescence in situ hybridization (FISH) method to analyze N-myc amplification in neuroblastoma and compare the findings with those using the Southern blot method.
Methods: In 26 neuroblastoma primary tumors and metastatic lesions, the N-myc amplification status was evaluated by both the Southern blot method and FISH method.
Results: Of the 22 samples with no N-myc amplification using Southern blot, no cells with N-myc amplification using FISH were present in 21 of the samples. However, one metastatic liver lesion showed 16% of the nuclei to display more than 10 copies of N-myc based on FISH analysis. In the 4 remaining samples with N-myc amplification using the Southern blot method (17 copies, 15 copies, 6 copies, and 3 copies), the rates of cells with more than 10 copies of N-myc based on a FISH analysis were 79%, 68%, 94%, and 9%, respectively.
Conclusions: The FISH method can detect more accurately N-myc amplification than the Southern blot method either when the rate of cells with N-myc amplification is low or intratumor heterogeneity is present. Copyright (C) 1999 by W.B. Saunders Company..
47. S Suita, T Tajiri, Y Sera, H Takamatsu, H Mizote, H Ohgami, N Kurosaki, T Hara, J Okamura, S Miyazaki, T Sugimoto, K Kawakami, M Tsuneyoshi, H Tasaka, H Yano, H Akiyama, K Ikeda, The characteristics of mediastinal neuroblastoma, EUROPEAN JOURNAL OF PEDIATRIC SURGERY, 10.1055/s-2000-12064, Vol.10, No.6, pp.353-359, 2000.12, The prognosis of mediastinal neuroblastoma has been reported to be better than for other neuroblastomas. The reason for this is however not clear, Furthermore, a comparison between mediastinal neuroblastoma and the other neuroblastomas has been rarely reported so far. In this study, the characteristics of mediastinal neuroblastoma (84 cases) are investigated and compared with those of other neuroblastomas (440 cases). Regarding clinical factors, the age distribution and the rate of cases detected at mass screening were similar in both groups. According to Evan's staging system, the rates of early stage (I, II) were 62% in the mediastinal neuroblastoma and 38% in the other neuroblastomas (p<0.001). Regarding the biological prognostic factors, a favorable histology based on Shimada's classification was found in 100% (35/35) of the mediastinal neuroblastoma cases and in 85% (112/132) of the other neuroblastoma cases (p < 0.05). With regard to N-myc amplification, all of the examined 42 cases in mediastinal neuroblastoma had a N-copy number of less than 10 copies, while 32 of the examined 263 cases (12%) in the other neuroblastomas had an amplification of N-myc of more than 10 copies (p < 0.05). The 5-year survival rates were 78% in the mediastinal neuroblastoma and 59% in the other neuroblastomas, respectively. Of the cases who underwent an incomplete resection of primary tumors in localized neuroblastoma, the 5-year survival rate of the mediastinal neuroblastoma cases was significantly more favorable than that of the other neuroblastomas. The majority of mediastinal neuroblastoma cases showed an early stage and favorable prognostic factors. It is likely that the clinical and biological prognostic factors of the tumor are therefore more closely correlated with the outcome of mediastinal neuroblastoma Father than the degree of the surgical resection. Regarding the treatment for mediastinal neuroblastoma, it is most important to evaluate the biology of the tumor after surgical resection..
48. S Suita, T Tajiri, Y Sera, H Takamatsu, H Mizote, A Nagasaki, N Kurosaki, T Hara, J Okamura, S Miyazaki, T Sugimoto, K Kawakami, H Eguchi, M Tsuneyoshi, Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification, JOURNAL OF PEDIATRIC SURGERY, 10.1053/jpsu.2000.19236, Vol.35, No.12, pp.1737-1741, 2000.12, Background/Purpose: In spite of many different kinds of chemotherapy for neuroblastoma, the prognosis for advanced neuroblastoma remains unsatisfactory. In particular, the outcome of advanced neuroblastoma with high copies of the N-myc gene tend to be poor. Therefore, the new high-dosage combined chemotherapy regimens for advanced neuroblastoma based in part on the N-myc amplification status has been utilized in the Kyushu area of Japan since 1991. This study aims to investigate whether these new regimens based in part on N-myc amplification have improved the survival rate of stage III and stage IV patients in comparison with the old regimens.
Methods: Between 1983 and 1995, 77 patients over 1 year of age and with stage III or IV neuroblastoma were registered in the Kyushu Area. Between 1983 and 1990, 49 patients received 1 of 2 combined chemotherapy regimens consisting of cyclophosphamide, cisplatin plus VM-26, and Adriamycin plus DTIC. Since 1991, two new regimens (New A1 and A3) have been administered based on the N-myc amplification status in a total of 28 patients. The New Al regimen, which consists of cyclophosphamide, cisplatin, Adriamycin, and VP-16 has been administered in cases of less than 10 copies of N-myc, whereas the A3 regimen, consisting of a higher dose of cyclophosphamide, cisplatin, Adriamycin, and VP-16, has been administered in cases of more than 10 copies of N-myc. The survival rate was then compared between the old regimens and the new regimens.
Results: The 3-year survival rate (61.5%) for patients treated by the new regimens was significantly higher than that (32.7%) for patients treated by the old regimens (P < .01). Regarding the 24 cases of more than 10 copies of N-myc, the 3-year survival rate (35.9%) of the 13 patients treated by the A3 regimen was higher than that (0%) of the 11 patients treated by the old regimens (P < .05). However, in the 19 stage IV patients treated by the new regimens, the 3-year survival rate (11.1%) of the 9 cases of more than 10 copies was significantly lower than that (77.8%) of the 10 cases of less than 10 copies of N-myc (P < .01).
Conclusions: These results suggest that high-dose combined chemotherapy based in part on the N-myc amplification status significantly improved the prognosis of patients with advanced neuroblastoma. However, stage IV patients with N-myc amplification still require a more effective treatment modality. J Pediatr Surg 35:1737-1741. Copyright (C) 2000 by W.B. Saunders Company..
49. K Shono, T Tajiri, Y Fujii, S Suita, Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma, JOURNAL OF PEDIATRIC SURGERY, 10.1053/jpsu.2000.16403, Vol.35, No.10, pp.1415-1420, 2000.10, Purpose: In patients with neuroblastoma (NB), minimal disease (MD) in bone marrow (BM) and peripheral blood (PB) is thought to play an important role in metastasis. The current study was designed to evaluate the clinical implications of the detection of MD in NE at the initial diagnosis.
Methods: Expression of the neuroendocrine protein gene product 9.5 (PGP9,5) and tyrosine hydroxylase (TH) mRNA in BM and PB obtained from 18 patients with NE was investigated by reverse transcriptase-polymerase chain reaction (RT-PCR),
Results: MD was detected in the BM obtained from 4 of 14 localized NE patients and also in the PB from 2, However, it was found also in both the BM and PB obtained from all 4 patients with metastatic NE. Two of the 4 MD-positive patients with localized NE had metastatic recurrence after a complete tumor excision, They also had unfavorable biological prognostic factors compared with the other 2 who did not have recurrent disease.
Conclusion: MD detected by RT-PCR in the BM and the PB of patients with NE thus suggests a risk for metastatic disease, which in association with other unfavorable biological features may indicate a poor prognosis, J Pediatr Surg 35:1415-1420. Copyright (C) 2000 by W.B. Saunders Company..
50. M Kubota, S Suita, T Tajiri, K Shono, Y Fujii, Analysis of the prognostic factors relating to better clinical outcome in ganglioneuroblastoma, JOURNAL OF PEDIATRIC SURGERY, Vol.35, No.1, pp.92-95, 2000.01, Purpose: To elucidate the precise reason for the better prognosis in ganglioneuroblastoma (GNB)than in neuroblastoma (NB), the prognostic factors (age at diagnosis, stage at diagnosis, primary site, N-myc amplification, Shimada classification, and ploidy) were analyzed.
Methods: A retrospective analysis of the 57 neuroblastoma cases (20 GNB cases and 37 NE cases), that had not been detected by mass screening over the past 19 years at the authors' institute, was carried out.
Results: A Kaplan-Meier analysis of the 5-year survival rates were 67.2% and 35.1% in cases of GNB and NE, respectively, and these rates were significantly higher in GNB (logrank test; P = .04631). No significant differences were seen between GNB and NE regarding the rate in patients 1 year of age or older (95.0% v78.4%; P = .1005), the rate of advanced cases (60.0% v78.4%, P = .1406), the rate of an unfavorable histology (Shimada classification, 54.5% v68.4%, P = .4473), or the diploid pattern rate (75.0% v76,9%, P = .9200). However, N-mycamplification was found exclusively in NE (amplified cases per examined cases; 15/31), and all cases with N-myc amplification died. When the 5-year survival rate was evaluated in the patient without N-myc amplification between GNB and NE, no significant difference was observed (logrank test; P = .8568).
Conclusion: The better prognosis in patients with GNB was thus thought to be exclusively related to an absence of N-myc amplification..
51. S Suita, K Shono, T Tajiri, T Takamatsu, H Mizote, A Nagasaki, Y Inomata, T Hara, J Okamura, S Miyazaki, K Kawakami, H Eguchi, M Tsuneyoshi, Malignant germ cell tumors: Clinical characteristics, treatment, and outcome. A report from the study group for pediatric solid malignant tumors in the Kyushu area, Japan, JOURNAL OF PEDIATRIC SURGERY, 10.1053/jpsu.2002.36700, Vol.37, No.12, pp.1703-1706, 2002.12, Purpose: This study aims to assess the prognostic factors and optimal treatments for malignant germ cell tumors (MGCT) in childhood.
Methods: Among 117 MGCT, the clinical features were analyzed. Regarding the histology, there were 89 embryonal carcinomas, 13 clysgerminomas, 4 choriocarcinomas, and 11 others. The prognostic factors and treatments were assessed based on the 5-year survival rate.
Results: (1) Stage: 100% for stage I (n = 54), 75.0% for stage 11 (n = 4), 67.3% for stage III (n = 14), and 54.8% for stage IV (n = 33); Unknown: n = 12. (2) Primary site: 93.4% for the testis (n = 52), 86.7% for the ovary (n = 31), 56.9% for the sacrococcygeal (n = 21), and 60.6% for others (n = 12); unknown: n = 1. (3) Surgical intervention for primary tumor: 100% for stage I with a complete resection (n = 53), 78.4% for stage III, IV with a complete resection (n = 26), and 33.3% for stage III, IV with an incomplete resection (n = 21). (4) Type of chemotherapy for the stage III and IV: 83.9% for the PVB (cisplatin, vinblastin, bleomycin; n = 13), 66.7% for the VAC (vincristine, actinomycin D, cyclophosphamide; n = 6), and 47.1% for other regimens (n = 25).
Conclusions: An early stage, a diagnosis under 1 year of age and a primary site in the gonads were favorable prognosis factors, whereas histologic findings of choriocarcinoma and liver or lung metastasis were unfavorable. Radical complete resection alone is a sufficient treatment for localized MGCT. The PVB regimen is optimal chemotherapy for advanced MGCT; however, high-risk cases still may require more aggressive treatment. Copyright 2002 Elsevier Science (USA). All rights reserved..
52. T Tajiri, K Shono, S Tanaka, S Suita, Evaluation of genetic heterogeneity in neuroblastoma, SURGERY, 10.1067/msy.2002.119964, Vol.131, No.1, pp.S283-S287, 2002.01, Background and Methods. The prognosis in neuroblastoma, which is the most common solid tumor in children, lends to vary greatly, and many studies have demonstrated both clinical and biological factors to he closely correlated with the outcome. In order to select the optimal treatment according to the degree of malignancy of neuroblastoma, it is essential to accurately and rapidly identify any genetic heterogeneity associated with the prognosis. We assessed the status of some genetic abnormalities (MYCN amplication, deletion of the short arm of chromosome 1, DNA ploidy, and a gain of the chromosome 17q region) associated with the prognosis using several moleculat biological methods.
Results and Conclusions. The combination of several molecular biological techniques is thus considered to be useful for elucidating the degree of malignancy of neuroblastoma. In particular, diagnostic analyses based on a combination of the fluorescence in situ hybridization (FISH) method and the quantitative polymerase chain reaction (PCR) method may be considered to be the most effective methods for quickly and accurately evaluating any aberrations in the gene dosages associated with the patients' outcomes..
53. S Suita, T Tajiri, H Takamatsu, H Mizote, A Nagasaki, Y Inomata, T Hara, J Okamura, S Miyazaki, K Kawakami, H Eguchi, M Tsuneyoshi, Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen - A report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu area, JOURNAL OF PEDIATRIC SURGERY, 10.1016/j.jpedsurg.2003.10.012, Vol.39, No.2, pp.195-198, 2004.02, Background/Purpose: The survival outcome for patients with hepatoblastoma normally depends on the resectability of the tumor. In Japan, the pre and/or postoperative chemotherapy protocol using a combination of cisplatin (CDDP) and tetrahydropyranyl-Adriamycin (THP-ADR) has been the standard treatment since 1991. This study aims to assess exactly what influence the establishment of this chemotherapy protocol has had on both the tumor resectability and the outcome of patients with hepatoblastoma.
Methods: From 1982 to 1997, 60 patients with hepatoblatoma were treated in the Kyushu area, Japan. Based on the pretreatment extent of disease (PRETEXT), the outcome and tumor resectability were compared between group A (1982 to 1990, n=27, PRETEXT I:5, II:8, III:6, IV:8) and group B (1991 to 1997, n=33, PRETEXT I:9, II:9, III:5, IV:10).
Results: The 5-year survival rates (group A and group B) were 33% and 73% for all cases (P<.01), 100% and 89% for PRETEXT I, 38% and 89% for II (P<.05),17% and 80% for III (P<.01), and 0% and 40% for IV (P<.01), respectively. The 5-year survival rates for patients with metastases were 0% for group A (n=5) and 57% for group B (n=7; P <.01). The rates of a complete resection of primary tumor were 48% for group A and 67% for group B. In particular, a significant difference was found regarding the complete resection rate between groups A and B in the patients with PRETEXT III (17% for group A and 80% for group B; P<.01). In the patients with an incomplete tumor resection (14 for group A, 11 for group B), the 5-year survival rates were 0% for group A and 45% for group B (P<.01).
Conclusions: The optimal chemotherapeutic regimen of CDDP and THP-ADR was thus found to greatly contribute to the improved survival rate of hepatoblastoma patients. Preoperative chemotherapy resulted in an increased resectability of the tumor, whereas postoperative chemotherapy played an important role in the increased cure rate of cases with either an incomplete tumor resection or metastasis. However, refractory cases with PRETEXT IV or metastasis may still require the development of an even more effective treatment modality, including the use of blood stem cell transplantation..
54. Malignant rhabdoid tumor of kidney with homozygous deletion of the hSNF5/INI1 gene.
55. M Hatano, H Takada, A Nomura, S Ohga, K Ohshima, Saeki, I, T Tajiri, T Taguchi, S Suita, T Hara, Epstein-Barr virus-associated bronchial leiomyoma in a boy with cellular immunodeficiency, PEDIATRIC PULMONOLOGY, 10.1002/ppul.20375, Vol.41, No.4, pp.371-373, 2006.04, Bronchial leiomyoma is a rare disease in children. Recently, the association of leiomyoma and HIV infection was reported. We describe a boy with a cellular immunodeficiency, who had endobronchial leiomyoma. The tumor cells were positive for Epstein-Barr virus-encoded RNA-1 (EBER-1) and Epstein-Barr virus-determined nuclear antigen-2, suggesting a role of Epstein-Barr virus in the pathogenesis of leiomyoma..
56. Sachiyo Suita, Yoshiaki Kinoshita, Tatsuro Tajiri, Toshiro Hara, Masazumi Tsuneyoshi, Hiroyoshi Mizote, Hiroko Inada, Hideo Takamatsu, Yoshifumi Kawano, Yukihiro Inomata, Akira Nagasaki, Yasuharu Ono, Noritoshi Handa, Jun Okamura, Eiichi Ishii, Kiyoshi Kawakami, Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu area, Japan, JOURNAL OF PEDIATRIC SURGERY, 10.1016/j.jpendsurg.2006.05.008, Vol.41, No.9, pp.1501-1505, 2006.09, Background/Purpose: Since 1996, the standard treatment of Wilms tumors in Japan has been based on the regimen of the Japanese Wilms Tumor Study. However, in Japan, there have been no reports about Wilms tumors that analyzed the clinical features and patient outcome in a large series until now. This study aims to assess the clinical characteristics of patients with Wilms tumor with a favorable histology from a retrospective standpoint in the Kyushu area in Japan and, furthermore, to analyze the historical changes of clinical features and outcome from the 1980s to the 1990s.
Methods: Between 1982 and 1996, 90 cases of Wilms tumors with a favorable histology were registered in the Kyushu area. Regarding the clinical feature and outcome, they were divided into 2 groups (group A, 1982-1989, n = 50; group B, 1990-1996, n = 40). The outcome was analyzed based on the 5-year overall survival rate.
Results: The clinical features (age, sex, initial symptom, location, stage) demonstrated no definite differences between group A and group B. Regarding the operation, the rate of an initial complete resection in the early stages was significantly higher in group B than in group A. All stage V cases in group B undewent a bilateral tumor biopsy instead of a radical nephrectomy as the initial operation. The 5-year overall survival rate throughout the whole period was 87.8%, whereas the rates were 84.0% for group A and 90.0% for group B (P = NS), respectively. Of particular note, the outcome of patients with stage I and stage V in group B substantially improved in comparison to that in group A. However, in advanced cases, no significant improvement in the outcome was noted.
Conclusions: This is the first report about the clinical features and outcome for Wilms tumors with a favorable histology in Japan from the 1980s to the 1990s. The present study suggested that in the early-stage cases, an initially complete resection followed by standard postoperative chemotherapy substantially improved the outcome of the patients in group B. In the stage V cases, the performance of renal salvage surgery may have positively contributed to the improvement in the outcome in group B. However, in the advanced stage cases, no definite improvement was noted. In the future, an improved efficacy of the treatments for Wilms tumors based on the standard protocol established by the Japanese Wilms Tumor Study in 1996 is expected in Japan. (c) 2006 Elsevier Inc. All rights reserved..
57. Sachiyo Suita, Tatsuro Tajiri, Michio Kaneko, Misako Hirai, Hideo Mugishima, Toru Sugimoto, Yoshiaki Tsuchida, Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy, JOURNAL OF PEDIATRIC SURGERY, 10.1016/j.jpedsurg.2006.10.056, Vol.42, No.3, pp.489-493, 2007.03, Background/Purpose: This study aims to clarify the implications of MYCN amplification in patients with high-risk neuroblastomas treated with 2 different regimens of induction chemotherapy established by the Japan Study Group for Advanced Neuroblastoma.
Methods: Between 1985 and 2003 in Japan, 392 patients with stage 4 neuroblastomas who were older than 12 months were treated with 2 regimens of induction chemotherapy (the combination of cyclophosphamide [CTX], cisplatin [CDDP], pirarubicin, and vincristine or etoposide). Regimen 91A3 or 98A3 (A3) (CTX 2400 mg/m(2), CDDP 125 mg/m(2)) was a higher dose combination of CTX and CDDP than regimen 85A1 or 91A1 (A1) (CTX 1200 mg/m(2), CDDP go mg/m(2)). The 392 cases were classified into 3 groups (A, I copy; B, 2-9 copies; C, more than 10 copies) based on the MYCN amplification status by a Southern blot analysis.
Results: The 5-year overall survival rate (5-YS) was 41.1% for all 392 cases. Regarding the MYCN amplification status, the 5-YS was 46.6% for A group (n = 227), 22.7% for B group (n = 26), and 36.0% for C group (n = 139). A flouresence in situ hybridization analysis showed the presence of the cells with more than 10 copies in cases with 2 to 9 copies based on the Southern blot findings. Of the 227 patients in a group, the 5-YS was 46.7% for the 70 cases treated by A3 and 47.0% for 154 cases treated by A I (nonsignificant). The 5-YS of the 210 patients with stem cell transplantation (SCT) (51.%) was significantly better than that of the 127 patients without SCT (41.1%) (P <.05).
Conclusions: Regarding the MYCN amplification status, the tumor aggressiveness might thus be different between 2 and 9 copies and a single copy of MYCN. In neuroblastomas with 2 and 9 copies of MYCN based on a Southern blot analysis, the MYCN amplification status should be analyzed using the flouresence in situ hybridization method. Induction chemotherapy followed by SCT according to the Japan Study Group for Advanced Neuroblastoma protocol improved the outcome of neuroblastomas with MYCN amplification; however, obtaining a further improvement in the long-term survival of stage 4 neuroblastomas may therefore require the development of an even more effective treatment modality. (c) 2007 Elsevier Inc. All rights reserved..
58. 小児固形悪性腫瘍におけるGlypican 3の発現の検討.
59. Yuhki Koga, Akinobu Matsuzaki, Aiko Suminoe, Natsumi Washitoh, Takuya Hara, Toshiro Hara, Akinobu Matsuzaki, Tatsuro Tajiri, Tomoaki Taguchi, Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma, PEDIATRIC BLOOD & CANCER, 10.1002/pbc.21309, Vol.50, No.4, pp.943-944, 2008.04.
60. A case of clear cell sarcoma of the kidney.
61. 小児固形悪性腫瘍におけるGlypican3の発現の検討(続報).
62. Sakura Tanaka, Yoshikazu Yonemitsu, Tatsuro Tajiri, Kyosuke Tatsuta, Yoshiaki Kinoshita, Ryota Souzaki, Yasuji Ueda, Yuki Koga, Aiko Suminoe, Akinobu Matsuzaki, Toshiro Hara, Mamoru Hasegawa, Tomoaki Taguchi, Dendritic Cell-Based Immunotherapy Using Sendai Virus Vector - A Preclinical Efficacy Study Against Neuroblastoma: An Advanced Report, MOLECULAR THERAPY, Vol.17, pp.S221-S222, 2009.05.
63. Sakura Tanaka, Kyosuke Tatsuta, Tatsuro Tajiri, Yosikazu Yonemitsu, Yasuji Ueda, Mamoru Hasegawa, Sachiyo Suita, Tomoaki Taguchi, DENDRITIC CELL-BASED IMMUNOTHERAPY USING SENDAI VIRUS VECTOR - A PRECLINICAL EFFICACY STUDY AGAINST NEUROBLASTOMA, JOURNAL OF GENE MEDICINE, Vol.11, No.12, pp.1172-1173, 2009.12.
64. 肝移植の適応・タイミング 肝移植のタイミングに難渋した巨大肝芽腫の1例
月齢3ヵ月女児。生後2ヵ月頃より黄疸、腹部膨満が出現し、CTで肝臓から骨盤腔に至る巨大腫瘤を認め、AFPは著明上昇していた。肝内4区域に浸潤を認め、門脈の左右枝も腫瘍に巻き込まれており、肝芽腫Pretreatment extent of disease IVと診断した。腫瘍全摘は困難と考え、化学療法7クールと肝動脈化学塞栓療法を行った。腫瘍は著明に縮小し、月齢8ヵ月に肝部分切除による腫瘍全摘術を行ったが、術後胆汁漏のため化学療法再開が遅れ、術後2ヵ月目に残肝後区域と尾状葉に肝内転移再発を来たした。再手術となったが、癒着が高度なため後区域切除にとどまり、尾状葉腫瘍にはマイクロ波凝固壊死療法を行った。術後化学療法を再開したが、肝機能障害および骨髄疲弊がみられ、再手術後3ヵ月ごろには残肝左葉にも転移巣を認めた。再手術後6ヵ月目に肝不全となり、母親をドナーとした生体肝移植術を行ったが、術後3日目に急激な肝機能障害を認め、敗血症とグラフト機能不全により術後5日目に死亡した。.
65. 当院における先天性門脈欠損症に対する生体肝移植の検討.
66. 小児外科基礎研究(腫瘍関連) 小児固形悪性腫瘍における新規腫瘍マーカーとしてのGlypican3の有用性.
67. 小児固形腫瘍に対する鏡視下生検の意義.
68. 小児に対するAugmented Reality手術ナビゲーションシステムの開発・導入.
69. Ryota Souzaki, Tatsuro Tajiri, Yoshiaki Kinoshita, Kohashi Kenichi, Yoshinao Oda, Tomoaki Taguchi, THE HEDGEHOG SIGNAL IN NEUROBLASTOMA, PEDIATRIC BLOOD & CANCER, Vol.55, No.5, p.895, 2010.11.
70. Eiso Hiyama, Arata Kamimatsuse, Naomi Kamei, Kenichiro Watanabe, Tomoro Hishiki, Tatsuro Tajiri, Komei Ida, Michihiro Yano, Satoshi Kondo, Fumiaki Sasaki, Hiroshi Horie, Naomi Ohnuma, OUTCOME OF HEPATOBLASTOMA TREATED WITH THE JPLT-2 PROTOCOL EFROM THE EXPERIENCE OF JPLT (JAPANESE STUDY GROUP FOR PEDIATRIC LIVER TUMOR) STUDY, PEDIATRIC BLOOD & CANCER, Vol.55, No.5, p.816, 2010.11.
71. E. Hiyama, A. Kamimatsuse, N. Kamei, K. Watanabe, T. Hishiki, T. Tajiri, K. Ida, M. Yano, S. Kondo, F. Sasaki, Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin and carboplatin chemotherapy for hepatoblastoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.28, No.15, 2010.05.
72. Tatsuro Tajiri, Ryota Souzaki, Yoshiaki Kinoshita, Akira Nakagawara, Tomoaki Taguchi, CONCORDANCE FOR NEUROBLASTOMA IN MONOZYGOTIC TWINS:A POSSIBILITY OF TWIN-TO-TWIN METASTASIS, PEDIATRIC BLOOD & CANCER, Vol.55, No.5, p.887, 2010.11.
73. Yoshiaki Kinoshita, Tanaka Sakura, Kohashi Kenichi, Tajiri Tatsuro, Souzaki Ryota, Oda Yoshinao, Taguchi Tomoaki, CLINICAL SIGNIFICANCE OF SERUM GLYPICAN 3 AS THE NOVEL DIAGNOSTIC MARKER, PEDIATRIC BLOOD & CANCER, Vol.55, No.5, p.977, 2010.11.
74. 小児腎腫瘍(九州地区登録例)の新病理分類に基づく解析 特に後腎芽細胞優位型.
75. 小児生体肝移植後の消化管穿孔における成績.
76. 小児におけるadvanced surgery 小児外科領域の希少疾患に対するAdvanced Surgery.
77. Ryota Souzaki, Tatsuro Tajiri, Risa Teshiba, Yoshiaki Kinoshita, Ryota Yosue, Kenich Kohashi, Yoshinao Oda, Tomoaki Taguchi, THE NUMBER OF SEGMENTAL CHROMOSOME ABERRATIONS SIGNIFICANTLY INCREASES IN PROPORTION TO THE AGE AT DIAGNOSIS IN SUBJECTS WITH DIPLOID/TETRAPLOID NEUROBLASTOMAS WITHOUT MYCN AMPLIFICATION, PEDIATRIC BLOOD & CANCER, Vol.57, No.5, p.783, 2011.11.
78. Tatsuro Tajiri, Ryota Souzaki, Yoshiaki Kinoshita, Ryota Yosue, Tomoaki Taguchi, SURGICAL INTERVENTION STRATEGIES FOR PEDIATRIC OVARIAN TUMORS: FROM THE EXPERIENCE OF 60 CASES IN ONE INSTITUTION, PEDIATRIC BLOOD & CANCER, Vol.57, No.5, p.756, 2011.11.
79. Tomoro Hishiki, Sasaki Fumiaki, Michihiro Yano, Kohmei Ida, Hiroshi Horie, Satoshi Kondo, Ken-Ichiro Watanabe, Takaharu Ooue, Tatsuro Tajiri, Arata Kamimatsuse, Eiso Hiyama, PRETREATMENT PROGNOSTIC FACTORS IN CHILDREN WITH HEPATOBLASTOMAS - A REPORT FROM THE JAPANESE STUDY GROUP FOR PEDIATRIC LIVER TUMOR (JPLT), PEDIATRIC BLOOD & CANCER, Vol.57, No.5, pp.728-729, 2011.11.
80. Tatsuro Tajiri, Osamu Kimura, Shigehisa Fumino, Tomoko Lehara, Hajime Hosoi, Ryota Souzaki, Yoshiaki Kinoshita, Tomoro Hishiki, Eiso Hiyama, Tomoaki Taguchi, SURGICAL STRATEGIES FOR HEPATOBLASTOMAS WITH PRETEXT III OR IV, PEDIATRIC BLOOD & CANCER, Vol.59, No.6, p.1021, 2012.12.
81. Eiso Hiyama, Arata Kamimatsuse, Kaoru Ogura, Tomoro Hishiki, Kenichiro Watanabe, Michihiro Yano, Satoshi Kondo, Tatsuro Tajiri, Kohmei Ida, Fumiaki Sasaki, Ifomide/pirarubicin/etoposide/carboplatin (ITEC) as second-line chemotherapy for hepatoblastoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.30, No.15, 2012.05.
82. Kenichiro Watanabe, Tomoro Hishiki, Kohmei Ida, Takaharu Ooue, Tatsuro Tajiri, Satoshi Kondo, Takehiko Kamijo, Shinichiro Nishimura, Hiroshi Horie, Eiso Hiyama, HEPATOBLASTOMA ASSOCIATED WITH BECKWITH-WIEDEMANN SYNDROME IN JAPAN: THE JPLT EXPERIENCE, PEDIATRIC BLOOD & CANCER, Vol.59, No.6, p.1069, 2012.12.
83. Shigehisa Fumino, Osamu Kimura, Taizo Furukawa, Shigeyoshi Aoi, Tomoko Iehara, Hajime Hosoi, Tatsuro Tajiri, CLINICAL FEATURES AND SURGICAL INTERVENTION OF RENAL TUMORS DIAGNOSED DURING EARLY INFANCY, PEDIATRIC BLOOD & CANCER, Vol.59, No.6, p.1135, 2012.12.
84. Eiso Hiyama, Arata Kamimatsuse, Yuka Ueda, Tomoro Hishiki, Michihiro Yano, Komei Ida, Satoshi Kondo, Kenichiro Watanabe, Takaharu Oue, Tatsuro Tajiri, Akira Nakagawara, Keiko Hiyama, A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NEW CANDIDATE LOCI ASSOCIATED WITH PROGRESSION OF HEPATOBLASTOMA IN JPLT2 STUDY EXPERIENCE, PEDIATRIC BLOOD & CANCER, Vol.59, No.6, pp.987-988, 2012.12.
85. Three patients with mesenteric lymphangioma encountered in our department.
86. 小児固形悪性腫瘍の予後追跡調査結果の報告 2001~2005年登録症例について.
87. How to treat infants with a variety of superficial or subcutaneous tumors.
88. M. Ohira, T. Kamijo, Y. Nakamura, K. Matsumoto, M. Kumagai, A. Nakazawa, T. Takimoto, T. Fukushima, T. Tajiri, H. Ikeda, A. Nakagawara, RISK CLASSIFICATION OF NEUROBLASTOMA BASED ON GENOMIC PROFILES: FOR FUTURE TAILOR-MADE THERAPEUTIC STRATEGIES IN JAPAN, PEDIATRIC BLOOD & CANCER, Vol.60, p.24, 2013.09.
89. Risa Teshiba, Tatsuro Tajiri, Kenzo Sumitomo, Kouji Masumoto, Tomoaki Taguchi, Ken Yamamoto, Identification of a KEAP1 Germline Mutation in a Family with Multinodular Goitre, PLOS ONE, 10.1371/journal.pone.0065141, Vol.8, No.5, p.e65141, 2013.05, Background: The familial clustering of multinodular goitres (MNGs) with a dominant mode of inheritance has been repeatedly reported. Linkage studies have revealed several genetic loci responsible for familial MNG; however, most of the causative variants remain unknown.
Methods and Results: Through linkage analysis using single-nucleotide polymorphism markers, we identified a new MNG locus on 19p13.2-q12 in a five-generation Japanese MNG family. Subsequent mutation searches focusing on the candidate 25-Mb region of chromosome 19 identified a heterozygous mutation, c. 879_880delinsA, p. Asp294Thr, fs*23, in exon 3 of the KEAP1, which plays a central role in the cytoprotection pathway against oxidative stress. Reverse transcriptase-PCR analysis showed low expression of wild type KEAP1 accompanied by no transcription product of mutant allele in the normal and goitre region of thyroid tissues obtained from the proband. In agreement with previous studies showing that KEAP1 negatively regulates NFE2L2, the NFE2L2 target genes GSTA4 and GCLC were up-regulated in the thyroid tissues of the patient.
Conclusions: This study identified the first KEAP1 mutation in MNG. The results provide insights into the pathogenesis of goitre which develops in the organ continuously exposed to oxidative stress during hormone synthesis..
90. E. Hiyama, Y. Ueda, Y. Onitake, K. Ida, K. Ogura, S. Kondo, T. Kamijyo, K. Watanabe, T. Oue, T. Hishiki, T. Tajiri, H. Horie, T. Inoue, Y. Tanaka, FURTHER STUDY: IDENTIFICATION OF NEW CANDIDATE GENES IN PROGRESSION OF HEPATOBLASTOMA USING GENOME-WIDE ASSOCIATION STUDY, PEDIATRIC BLOOD & CANCER, Vol.60, pp.17-18, 2013.09.
91. T. Iehara, K. Tsuchiya, S. Yagyu, K. Ouchi, K. Sakamoto, M. Miyachi, Y. Katsumi, Y. Kuwahara, S. Fumino, T. Tajiri, H. Hosoi, DOES A RESIDUAL TUMOR MASS IN CASES OF INTERMEDIATE-RISK NEUROBLASTOMA INFLUENCE THE PROGNOSIS?, PEDIATRIC BLOOD & CANCER, Vol.60, p.113, 2013.09.
92. S. Fumino, O. Kimura, T. Furukawa, S. Aoi, K. Higuchi, T. Iehara, H. Hosoi, T. Tajiri, CLINICAL FEATURES AND SURGICAL INTERVENTION OF PRIMARY MEDIASTINAL TUMORS IN CHILDREN: A 25-YEAR SINGLE INSTITUTION EXPERIENCE, PEDIATRIC BLOOD & CANCER, Vol.60, p.46, 2013.09.
93. 神経芽腫マススクリーニングを考える 神経芽腫マス・スクリーニング休止後の臨床像の変化 小児の外科的悪性腫瘍登録データの解析より.
94. 甲状腺髄様癌多発転移を有するMEN2B女性例の長期経過.
95. 日本小児外科学会の悪性腫瘍登録事業における倫理課題.
96. 小児の外科的悪性腫瘍、2012年登録症例の全国集計結果の報告.
97. 専門医制度における現状と今後の課題 小児血液・がん領域から求められる小児外科医の理想像 小児がん認定外科医の現状と問題点からの考察.
98. 先天性巨大エプーリスの1例.
99. S. Fumino, K. Kimura, T. Iehara, N. Motoki, N. Satoaki, R. Souzaki, A. Nishie, T. Taguchi, H. Hosoi, T. Tajiri, VALIDITY AND RELIABILITY OF IMAGE-DEFINED RISK FACTORS IN LOCALIZED NEUROBLASTOMA: A REPORT FROM 2 TERRITORIAL CENTERS IN JAPAN, PEDIATRIC BLOOD & CANCER, Vol.61, p.S208, 2014.12.
100. T. Iehara, K. Tsuchiya, K. Ouchi, M. Miyachi, Y. Kuwahara, S. Fumino, T. Tajiri, H. Hosoi, CLINICAL FINDINGS OF ONCOLOGIC EMERGENCY AT DIAGNOSIS, PEDIATRIC BLOOD & CANCER, Vol.61, p.S191, 2014.12.
101. A. Yoneda, T. Tajiri, T. Iehara, M. Kitamura, A. Nakazawa, H. Takahashi, T. Takimoto, A. Nakagawara, CHARACTERTICS OF IMAGE DEFINED RISK FACTORS (IDRFS) IN PATIENTS ENROLLED THE LOW RISK PROTOCOL (JNB-L-10) FROM THE JAPANESE NEUROBLASTOMA STUDY GROUP (JNBSG), PEDIATRIC BLOOD & CANCER, Vol.61, p.S207, 2014.12.
102. 小児の外科的悪性腫瘍、2013年登録症例の全国集計結果の報告.
103. K. Matsumoto, M. Ohira, T. Kamijo, H. Shichino, T. Kuroda, T. Hishiki, T. Soejima, T. Kaneko, A. Nakazawa, T. Takimoto, T. Fukushima, J. Hara, M. Kaneko, H. Ikeda, T. Tajiri, A. Nakagawara, MOLECULAR PROFILING INCLUDING GENOMIC ABERRATIONS CAN REVEAL ULTRA HIGH-RISK GROUP IN THE JAPAN NEUROBLASTOMA STUDY GROUP'S CLINICAL TRIAL FOR HIGH-RISK NEUROBLASTOMA, PEDIATRIC BLOOD & CANCER, Vol.62, p.S225, 2015.11.
104. A. Yoneda, T. Tajiri, E. Hiyama, T. Iehara, T. Hishiki, K. Sugito, Y. Hayashi, K. Maeda, T. Yonekura, CHANGES IN THE CLINICAL FEATURES OF NEUROBLASTOMA 10 YEARS AFTER THE CESSATION OF MASS SCREENING IN JAPAN, PEDIATRIC BLOOD & CANCER, Vol.62, p.S177, 2015.11.
105. 6ヵ月マススクリーニング休止後10年間の小児の外科的悪性腫瘍登録データ解析による神経芽腫臨床像の変化.
106. 縦隔腫瘍術後乳び胸に対する胸腔鏡下PGAシート+フィブリン糊被覆法による治療経験.
107. 巨大縦隔悪性胚細胞腫瘍の1例.
108. Yoshiyuki Takahashi, Atsushi Narita, Nikolai Siebert, Nobuhiro Nishio, Yinyan Xu, Hideki Muramatsu, Asahito Hama, Takehiko Kamijo, Atsuko Nakazawa, Hajime Hosoi, Yoshiaki Kinoshita, Shinobu Shimizu, Katsuyoshi Kato, Masaaki Mizuno, Hans Loibner, Tatsuro Tajiri, Akira Nakagawara, Ruth Ladenstein, Holger N. Lode, Seiji Kojima, Phase I bridging study of ch14.18/CHO long-term infusion in recurrent or refractory neuroblastoma patients in Japan., JOURNAL OF CLINICAL ONCOLOGY, 10.1200/JCO.2016.34.15_suppl.10568, Vol.34, No.15, 2016.05.
109. S. Fumino, J. Maniwa, Y. Takeuchi, K. Sakai, M. Higashi, S. Aoi, T. Furukawa, O. Kimura, T. Tajiri, Perioperative Management and Surgical Intervention for Retroperitoneal Teratomas in Children, PEDIATRIC BLOOD & CANCER, Vol.63, p.S47, 2016.11.
110. H. Shichino, H. Mugishima, K. Matsumoto, T. Hishiki, T. Iehara, A. Yoneda, T. Soejima, T. Takimoto, H. Takahashi, S. Teramukai, T. Kamijo, A. Nakazawa, T. Fukushima, H. Hosoi, T. Tajiri, A. Nakagawara, A Phase II Study of Bold Delayed Local Control Strategy in Children with High Risk Neuroblastoma: Japan Neuroblastoma Study Group (JN-H-11) Trial, PEDIATRIC BLOOD & CANCER, Vol.63, p.S203, 2016.11.
111. 臨床試験から視た小児手術 JCCG神経芽腫委員会外科療法委員会の活動と最近のプロトコール治療による外科治療について.
112. A Case of Solid-Pseudopapillary Neoplasm of the Pancreas in a 12-Year-Old Girl Treated by Laparoscopic Spleen-Preserving Distal Pancreatectomy.
113. Junnosuke Maniwa, Koseki Kimura, Shigehisa Fumino, Tomoko Tanaka, Mayumi Higashi, Kohei Sakai, Shigeyoshi Aoi, Taizo Furukawa, Tsunao Kishida, Osamu Matsuda, Tatsuro Tajiri, Tumor-homing Effect of Homogenic Mouse-derived Mesenchymal Stem Cells Using the TH-MYCN Mouse Model of Neuroblastoma, PEDIATRIC BLOOD & CANCER, Vol.64, p.S104, 2017.11.
114. Mayumi Higashi, Kiyokazu Kin, Tomoko Tanaka, Yuki Takeuchi, Shigehisa Fumino, Tatsuro Tajiri, Sphere Formation of Neural Stem-like Cells Derived from Human Immature Teratoma, PEDIATRIC BLOOD & CANCER, Vol.64, p.S66, 2017.11.
115. Tomoko Tanaka, Yuki Takeuchi, Mayumi Higashi, Shigehisa Fumino, Tomoko Iehara, Hajime Hosoi, Toshiyuki Sakai, Tatsuro Tajiri, Pre- and Post-chemotherapeutic Phosphorylated-ERK Immunohistochemical Staining in Clinical Neuroblastoma Samples: As a Possible Biomarker of Novel MEK Inhibitor Treatment, PEDIATRIC BLOOD & CANCER, Vol.64, pp.S46-S47, 2017.11.
116. Takafumi Kawano, Ryota Sozaki, Tomoro Hishiki, Yoshiaki Kinoshita, Tatsuro Tajiri, Akihiro Yoneda, Takaharu Oue, Tsugumichi Koshinaga, Eiso Hiyama, Masaki Nio, Yukihiro Inomata, Tatsuo Kuroda, Tomoaki Taguchi, Satoshi Ieiri, Possibility of Standardization for Endoscopic Surgery of Neuroblastoma: Results from a Nationwide Survey in Japan, PEDIATRIC BLOOD & CANCER, Vol.64, pp.S47-S48, 2017.11.
117. Masaya Suematsu, Shigeki Yagyu, Sachiko Gotoh, Mitsuru Miyachi, Hitoshi Tonomura, Takumi Yamanaka, Shigehisa Fumino, Taizo Furukawa, Kunihiko Tsuchiya, Tomoko Iehara, Naoya Hashimoto, Shigeru Ono, Tatsuro Tajiri, Hajime Hosoi, Mediastinal Neuroblastoma Presenting as an Oncologic Emergency - Usefulness of Serum-based MYCN Gene Amplification Analysis for Risk Stratification, PEDIATRIC BLOOD & CANCER, Vol.64, p.S48, 2017.11.
118. T. Iehara, I. Yokota, A. Yoneda, T. Kamijo, A. Nakazawa, A. Kikuta, T. Takimoto, S. Teramukai, H. Hajime, A. Nakagawara, T. Tajiri, Interim Results of a Clinical Trial of IDRF for Intermediate-Risk Neuroblastoma from the Japan Neuroblastoma Study Group (JNBSG), PEDIATRIC BLOOD & CANCER, Vol.64, pp.S229-S230, 2017.11.
119. Yuki Takeuchi, Tomoko Tanaka, Mayumi Higashi, Shigehisa Fumino, Tomoko Iehara, Hajime Hosoi, Toshiyuki Sakai, Tatsuro Tajiri, In vivo Effects of Novel MEK Inhibitors on Neuroblastoma and the Biomarker for their Therapeutic Effects in Neuroblastoma Xenograft Mice, PEDIATRIC BLOOD & CANCER, Vol.64, p.S47, 2017.11.
120. S. Fumino, K. Sakai, M. Higashi, S. Aoi, T. Furukawa, M. Yamagishi, M. Inoue, T. Iehara, H. Hosoi, T. Tajiri, Current Surgical Intervention for Pediatric Giant Mediastinal Germ Cell Tumors, PEDIATRIC BLOOD & CANCER, Vol.64, pp.S93-S94, 2017.11.
121. Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Kunihiko Tsuchiya, Tomoko Iehara, Ryu Terauchi, Toshiharu Shirai, Eiichi Konishi, Shigehisa Fumino, Tatsuro Tajiri, Hajime Hosoi, Combined Surgery and Radiation Therapy Results in Excellent Local Control in Axial Ewing Sarcoma Family of Tumors, PEDIATRIC BLOOD & CANCER, Vol.64, pp.S58-S59, 2017.11.
122. Shigehisa Fumino, Noriaki Usui, Masanori Tamura, Haruhiko Sago, Shigeru Ono, Shunsuke Nosaka, Akihiro Yoneda, Ryota Souzaki, Mayumi Higashi, Kohei Sakai, Hisanori Sobajima, Takahashi Ken, Takahiro Sugiura, Tomoaki Taguchi, Tatsuro Tajiri, Clinical Practice Guidelines for Infantile Sacrococcygeal Teratoma in Japan, PEDIATRIC BLOOD & CANCER, Vol.64, pp.S66-S67, 2017.11.
123. 術前3D-CTが有用であった乳児巨大後腹膜奇形腫の一摘除例.
124. 神経芽腫に対する内視鏡外科手術の適応基準の作成と標準化へ向けた挑戦 全国調査からみた現状と集約化および臨床試験へ向けた可能性.
125. 神経芽腫に対する内視鏡外科手術の適応基準の作成と標準化へ向けた挑戦 全国調査からみた現状と集約化および臨床試験へ向けた可能性.
126. 神経芽腫に対する内視鏡外科手術の適応基準の作成と標準化へ向けた挑戦 全国調査からみた現状と集約化および臨床試験へ向けた可能性.
127. 日本小児外科学会における小児の外科的悪性腫瘍の登録について(これまでとこれから).
128. 小児固形悪性腫瘍の予後追跡調査結果の報告 2006~2010年登録症例について.
129. 小児の外科的悪性腫瘍、2016年登録症例の全国集計結果の報告.
130. QOLを重視した小児がんにおける局所治療(外科療法と放射線療法)の現状と今後 小児がんの粒子線治療における吸収性スペーサーの開発に向けて.
131. 小児の外科的悪性腫瘍、2017年登録症例の全国集計結果の報告.
132. Akihiro Yoneda, Tomoro Hishiki, Tatsuro Tajiri, Tomoko Iehara, Kimikazu Matsumoto, Hiroyuki Shichino, Akira Nakagawara, Surgical Strategy in the JCCG Neuroblastoma Committee (JNBSG) Clinical Trials, PEDIATRIC BLOOD & CANCER, Vol.66, p.S4, 2019.12.